共 50 条
Engineering Strategies to Modulate the Gut Microbiome and Immune System
被引:3
|作者:
Han, Kai
[1
,2
,3
]
Xu, Jin
[1
,3
]
Xie, Fang
[1
,3
]
Crowther, Julia
[1
,3
]
Moon, James J.
[1
,3
,4
,5
]
机构:
[1] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] China Pharmaceut Univ, Dept Pharmaceut, State Key Lab Nat Med, Nanjing, Peoples R China
[3] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA
来源:
关键词:
CHAIN FATTY-ACIDS;
INTESTINAL MICROBIOTA;
DIETARY FIBER;
DELIVERY;
HOMEOSTASIS;
PRINCIPLES;
PROBIOTICS;
D O I:
10.4049/jimmunol.2300480
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The gut microbiota, predominantly residing in the colon, is a complex ecosystem with a pivotal role in the host immune system. Dysbiosis of the gut microbiota has been associated with various diseases, and there is an urgent need to develop new therapeutics that target the microbiome and restore immune functions. This Brief Review discusses emerging therapeutic strategies that focus on oral delivery systems for modulating the gut microbiome. These strategies include genetic engineering of probiotics, probiotic-biomaterial hybrids, dietary fibers, and oral delivery systems for microbial metabolites, antimicrobial peptides, RNA, and antibiotics. Engineered oral formulations have demonstrated promising outcomes in reshaping the gut microbiome and influencing immune responses in preclinical studies. By leveraging these approaches, the interplay between the gut microbiota and the immune system can be harnessed for the development of novel therapeutics against cancer, autoimmune disorders, and allergies. The Journal of Immunology, 2024, 212: 208-215.
引用
收藏
页码:208 / 215
页数:9
相关论文